HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) trials appear
Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare bleeding disorder: drug VAD044 targets nosebleeds
Disease control OngoingThis study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The first part compares two doses of VAD044 against a placebo to see if it safely reduces nosebleeds. The second part i…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Phase: PHASE1, PHASE2 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated May 26, 2026 10:03 UTC
-
Can a cancer drug tame HHT's dangerous heart and liver complications?
Disease control ENROLLING_BY_INVITATIONThis study looks at how well and how safely the drug bevacizumab works for people with hereditary hemorrhagic telangiectasia (HHT) who have severe liver issues causing high heart output and possible heart failure. Researchers will check heart function before and after 6 months of…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated May 26, 2026 09:51 UTC
-
Hope for HHT: drug shows promise in controlling nosebleeds
Disease control OngoingThis study looks at the long-term safety and effectiveness of pomalidomide in people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent bleeding, especially from the nose. It follows 62 adults who previously took part in a clinical trial of pomalid…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
HHT drug trial halted before it began
Disease control TerminatedThis study was designed to test a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and abnormal blood vessels. The trial was withdrawn before enrolling any participants, so no results are available. …
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Phase: PHASE1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC